How to buy Edgewise Therapeutics stock | $16.7

Edgewise Therapeutics Inc is a biotechnology business based in the US. Edgewise Therapeutics shares (EWTX) are listed on the NASDAQ and all prices are listed in US Dollars. Edgewise Therapeutics employs 26 staff and has a market cap (total outstanding shares value) of 0.00.

Edgewise Therapeutics stock price (NASDAQ: EWTX)

Use our graph to track the performance of EWTX stocks over time.

Edgewise Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-23.

Latest market close	$16.70
52-week range	$13.60 - $40.49
50-day moving average	$17.36
200-day moving average	$21.93
Wall St. target price	$31.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.05

Buy Edgewise Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Edgewise Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Edgewise Therapeutics price performance over time

Historical closes compared with the close of $16.7 from 2021-10-22

1 week (2021-10-18)	-3.86%
1 month (2021-09-24)	-8.19%
3 months (2021-07-26)	-17.29%
6 months (2021-04-26)	-37.80%

1 year (2020-10-22)	N/A
2 years (2019-10-22)	N/A
3 years (2018-10-22)	N/A
5 years (2016-10-22)	N/A

Edgewise Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-13.8%
Return on equity TTM	-22.8%
Profit margin	0%
Book value	$6.02
Market capitalisation	$822.7 million

TTM: trailing 12 months

Shorting Edgewise Therapeutics shares

There are currently 1.6 million Edgewise Therapeutics shares held short by investors – that's known as Edgewise Therapeutics's "short interest". This figure is 0.8% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Edgewise Therapeutics shares can be evaluated.

Edgewise Therapeutics's "short interest ratio" (SIR)

Edgewise Therapeutics's "short interest ratio" (SIR) is the quantity of Edgewise Therapeutics shares currently shorted divided by the average quantity of Edgewise Therapeutics shares traded daily (recently around 70513.273942094). Edgewise Therapeutics's SIR currently stands at 22.45. In other words for every 100,000 Edgewise Therapeutics shares traded daily on the market, roughly 22450 shares are currently held short.

To gain some more context, you can compare Edgewise Therapeutics's short interest ratio against those of similar companies.

• Alexion Pharmaceuticals (ALXN.US): 5.36
• Biohaven Pharmaceutical Holding Company (BHVN.US): 8.57
• aTyr Pharma (LIFE.US): 0.11

However Edgewise Therapeutics's short interest can also be evaluated against the total number of Edgewise Therapeutics shares, or, against the total number of tradable Edgewise Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Edgewise Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Edgewise Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0812% of the tradable shares (for every 100,000 tradable Edgewise Therapeutics shares, roughly 81 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Edgewise Therapeutics.

Find out more about how you can short Edgewise Therapeutics stock.

Edgewise Therapeutics share dividends

We're not expecting Edgewise Therapeutics to pay a dividend over the next 12 months.

Edgewise Therapeutics overview

Edgewise Therapeutics, Inc. , a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado. .

Frequently asked questions

What percentage of Edgewise Therapeutics is owned by insiders or institutions?
Currently 1.101% of Edgewise Therapeutics shares are held by insiders and 103.551% by institutions. How many people work for Edgewise Therapeutics?
Latest data suggests 26 work at Edgewise Therapeutics. When does the fiscal year end for Edgewise Therapeutics?
Edgewise Therapeutics's fiscal year ends in December. Where is Edgewise Therapeutics based?
Edgewise Therapeutics's address is: 3415 Colorado Avenue, Boulder, CO, United States, 80303 What is Edgewise Therapeutics's ISIN number?
Edgewise Therapeutics's international securities identification number is: US28036F1057